Novo Nordisk
Pharmaceutical company making diabetes, obesity and rare disease medicines and injection pens for patients in France
Highlights
- New on EvolcAdded 2026-10-28
About Novo Nordisk
Novo Nordisk France is the French subsidiary of the Novo Nordisk biopharmaceutical group. It develops medicines and delivery devices such as pen injectors, and its research is expanding from diabetes into cardio-metabolic diseases.
Its treatments cover diabetes, obesity, rare bleeding disorders and growth disorders. The customers are patients living with chronic diseases. The group states a focus on serious chronic conditions and a long-term commitment to insulin, which it marks with a 100-year anniversary.
The French entity was founded in 2003 and is headquartered in Puteaux. It also has a site in Chartres and an office at La Défense. The company runs programmes for young professionals and lists current job openings.
Product: Prescription medicines and drug delivery devices such as pen injectors for diabetes, obesity, rare bleeding disorders and growth disorders.
Public tenders won
4 tenders won since 1 Jan 2024 from 3 public buyers in France, worth €3.3B as awarded. From EU award notices (TED) that name Novo Nordisk by its registry number.
- 20 Aug 2025 CHU Rouen Normandie · Fourniture de médicaments dérivés du sang pour le CHU Rouen Normandie · €10.8M notice
- 20 Jun 2025 Hospices Civils de Lyon · MS7-UNIHA-Fourniture de Médicaments Dérivés du Sang, Recombinants et Issus de Thérapie Génique · €103.2M notice
- 16 May 2025 GCS GRAPS GRAND EST · Fourniture de spécialités pharmaceutiques au profit des adhérents du GCS GRAPS Grand Est notice
- 30 Apr 2025 Hospices Civils de Lyon · Les Hospices Civils de Lyon sont pourvoir adjudicateur et coordonnateur du groupement de commandes pour la " Fourniture de Médicaments Dérivés du Sang, Recombinants et Issus de Thérapie Génique". · €3.2B notice
Jobs at Novo Nordisk
More biotech & pharma companies
Ocean DX
Molecular diagnostic kit that identifies sepsis-causing bacteria in blood within about 5 hours, for hospitals and cliniciansNew on EvolcOddifact
AI platform that prepares orphan drug programs for rare diseases and hands them to pharma partners for developmentYoung companyNew on EvolcOGD2 Pharma
Biotherapy developer targeting the tumour-restricted OAcGD2 antigen for high-risk neuroblastoma treatmentNew on EvolcOncodesign Services
Preclinical CRO running in vivo pharmacology, imaging and radiopharmaceutical studies for biotech and pharma sponsorsRemote-friendlyOne Biosciences
Single-cell tumour profiling from biopsy samples for oncologists and pharma and biotech drug developersNew on EvolcOrakl Oncology
Oncology drug discovery and clinical-response prediction for biopharma companies and research hospitalsYoung companyNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Fastly
- OneTrust